Lloyd C E, Sartorius N, Cimino L C, Alvarez A, Guinzbourg de Braude M, Rabbani G, Uddin Ahmed H, Papelbaum M, Regina de Freitas S, Ji L, Yu X, Gaebel W, Müssig K, Chaturvedi S K, Srikanta S S, Burti L, Bulgari V, Musau A, Ndetei D, Heinze G, Romo Nava F, Taj R, Khan A, Kokoszka A, Papasz-Siemieniuk A, Starostina E G, Bobrov A E, Lecic-Tosevski D, Lalic N M, Udomratn P, Tangwongchai S, Bahendeka S, Basangwa D, Mankovsky B
Faculty of Health & Social Care, The Open University, UK.
Association for the Improvement of Mental Health Programmes (AMH), Geneva, Switzerland.
Diabet Med. 2015 Jul;32(7):925-34. doi: 10.1111/dme.12719. Epub 2015 Feb 27.
People with diabetes are at an increased risk of developing depression and other psychological disorders. However, little is known about the prevalence, correlates or care pathways in countries other than the UK and the USA. A new study, the International Prevalence and Treatment of Diabetes and Depression Study (INTERPRET-DD) aims to address this dearth of knowledge and identify optimal pathways to care across the globe.
INTERPRET-DD is a 2-year longitudinal study, taking place in 16 countries' diabetes outpatients' facilities, investigating the recognition and management of depressive disorders in people with Type 2 diabetes. Clinical interviews are used to diagnose depression, with clinical and other data obtained from medical records and through patient interviews. Pathways to care and the impact of treatment for previously unrecognized (undocumented) depression on clinical outcomes and emotional well-being are being investigated.
Initial evidence indicates that a range of pathways to care exist, with few of them based on available recommendations for treatment. Pilot data indicates that the instruments we are using to measure both the symptoms and clinical diagnosis of depression are acceptable in our study population and easy to use.
Our study will increase the understanding of the impact of comorbid diabetes and depression and identify the most appropriate (country-specific) pathways via which patients receive their care. It addresses an important public health problem and leads to recommendations for best practice relevant to the different participating centres with regard to the identification and treatment of people with comorbid diabetes and depression.
糖尿病患者患抑郁症及其他心理障碍的风险增加。然而,除了英国和美国之外,其他国家关于抑郁症的患病率、相关因素或护理途径的了解甚少。一项新的研究,即国际糖尿病与抑郁症患病率及治疗研究(INTERPRET-DD)旨在填补这一知识空白,并确定全球范围内最佳的护理途径。
INTERPRET-DD是一项为期2年的纵向研究,在16个国家的糖尿病门诊机构开展,调查2型糖尿病患者中抑郁症的识别与管理情况。通过临床访谈诊断抑郁症,并从病历及患者访谈中获取临床及其他数据。正在研究护理途径以及对先前未被识别(未记录)的抑郁症进行治疗对临床结局和情绪健康的影响。
初步证据表明存在多种护理途径,但很少有基于现有治疗建议的。试点数据表明,我们用于测量抑郁症症状和临床诊断的工具在我们的研究人群中是可接受的且易于使用。
我们的研究将增进对糖尿病合并抑郁症影响的理解,并确定患者接受护理的最合适(针对特定国家)途径。它解决了一个重要的公共卫生问题,并为不同参与中心在识别和治疗糖尿病合并抑郁症患者方面的最佳实践提供建议。